Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression.
Tanabe
K
K
Department of Urology and Surgery, Tokyo Women's Medical College, Japan.
Koga
S
S
Takahashi
K
K
Sonda
K
K
Tokumoto
T
T
Babazono
T
T
Yagisawa
T
T
Toma
H
H
Kawai
T
T
Fuchinoue
S
S
Teraoka
S
S
Ota
K
K
D000293:Adolescent; D000328:Adult; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000453:epidemiology*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011183:Postoperative Complications; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016559:Tacrolimus; D008775:Methylprednisolone